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Abstract The androgen receptor (AR) is a widely expressed
ligand-activated transcription factor which mediates androgen
signalling by binding to androgen response elements (AREs)
in normal tissue and prostate cancer (PCa).Within tumours, the
amount of AR plays a crucial role in determining cell growth,
resistance to therapy and progression to fatal castrate recurrent
PCa in which prostate cells appear to become independent of
androgenic steroids. Despite the pivotal role of the AR in male
development and fertility and all stages of PCa development,
the mechanisms governing AR expression remain poorly un-
derstood. In this work, we describe an active nonconsensus
androgen response element (ARE) in the 5′UTR of the human
AR gene. The ARE represses transcription upon binding of
activated AR, and this downregulation is relieved by disruption
of the regulatory element through mutation. Also, multiple
species comparison of the genomic region reveals that this
ARE is specific to primates, leading to the conclusion that care
must be exercisedwhen elucidating the operation of the human
AR in PCa based upon rodent promoter studies.
Introduction
In male humans, androgens induce development of the pros-
tate gland during the second and third trimester from the
endodermally derived urogenital sinus through epithelial-
mesenchymal interactions that lead to epithelial proliferation,
invasion, and bud formation (reviewed in Prins and Putz [1]).
Circulating testosterone is reduced to the more potent dihy-
drotestosterone (DHT) that binds to the androgen receptor
(AR) causing transformational change and activation.
Thereafter, the androgen receptor choreographs differentiation
and growth of normal prostate epithelial cells through the
coordination of multiple signalling pathways and develop-
mental genes including sonic hedgehog (Ssh), the Notch path-
way, wnt operating through nuclear β-catenin, Nkx3.1,
Hoxb13 and Sox9. Unfortunately, the AR signalling axis can
also actuate and stimulate carcinogenesis of the prostate, and
prostate cancer (PCa) is now the second most common cancer
in men in Western nations, with comparable figures rising in
Asian countries [2].
Although multiple mechanisms contribute to the le-
thal progression from benign prostatic hyperplasia to
metastatic cancer, AR-mediated cell signalling continues
to govern cell growth and survival [3–5] with many of
the androgen-induced developmental programmes being
reactivated in an aberrant manner during malignant
prostatic initiation and growth [6], e.g. overexpression
of β-catenin [7] and Sox9 [8]. Consequently, androgen
ablation therapy through inhibition of AR function with
antagonists or abatement of testicular or intratumoural
androgen synthesis form the basis of treatment [3, 9].
Tumours invariably advance to a state referred to as
castrate recurrent PCa (CRPC) [10] where they become
independent of circulating androgen with a concomitant
bleak prognosis [11]. Androgen signalling plays a piv-
otal role in PCa and increased AR expression is a
common feature of both primary tumours and metasta-
ses, with a high AR profile in the latter correlating to
larger tumour size [12]. The majority of CRPC tumours
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overexpress AR [13–15], and the AR gene is amplified
in approximately a third of cases [16]. The resulting
elevated levels of receptor allow cancer cells to be
stimulated by low concentrations of androgen [17],
which continue to be synthesised in CRPC [18], and
afford protection from high-dose antiandrogen therapy,
e.g. treatment with bicalutimide [19].
The androgen receptor exerts its influence by acting
as an androgen-activated transcription factor which
binds to androgen response elements (AREs) [3] where
hierarchical complexes of cofactors and other transcrip-
tion factors govern the transcriptional response [20].
The binding of AR to AREs can elicit stimulation or
repression depending upon the relative intracellular con-
centrations of coactivators and corepressors, and the
specific sequence of the ARE and surrounding chroma-
tin architecture [21]. Within the PCa genome, the over-
whelming majority of delineated AR binding sites (86
to 95 %) are located outside the promoters of AR
responsive genes necessitating chromatin looping [22].
The human single copy AR gene is located at Xq11.2-
q12 and possesses a promoter lacking TATA and CAAT
boxes, and several regulatory elements have been
mapped (see [23] for review). The 4.3-kb AR transcript
has an unusually long 5′ untranslated region (5′ UTR)
of 1.1 kb. It has been recognised for some time that the
AR gene is subject to auto-downregulation in many
androgen target tissues, including the human PCa cell
line LNCaP, with the androgen-mediated response oc-
curring at the level of reduced messenger RNA (mRNA)
transcription [24–29].
Despite the fundamental importance of AR levels in all
stages of PCa progression, the cis-acting regulatory se-
quences involved in androgen-mediated downregulation
of AR mRNA remain poorly understood with only one
site in the second intron described in detail to date [30].
Conversely, four AREs located within exons 4 and 5 have
been identified and shown to mediate AR-dependent up-
regulation of receptor mRNA (reviewed in [31]). In this
report, we describe an active nonconsensus androgen re-
sponse element in the 5′ UTR of the human AR gene that
binds AR and elicits repression of AR transcription.
Disruption of the ARE by mutation relieves this negative
regulation of the AR gene in PCa cell lines expressing AR
but not in DU145 which does not express endogenous
AR. Therefore, the potential detrimental effects of andro-
gen deprivation therapy (ADT) on PCa tumour develop-
ment through increased AR transcription should be borne
in mind. Lastly, comparison of the genomic region in
multiple species reveals that this ARE is specific to pri-
mates, necessitating caution in extrapolating findings
from rodent promoter studies to the etiology and treat-
ment of prostate cancer.
Materials and Methods
Cell Culture
Human prostate carcinoma cell lines LNCaP and VCaP were
obtained from the European Collection of Cell Cultures, and
DU145 was from the American Type Culture Collection.
VCaP and DU145 were grown in DMEM while LNCaP were
maintained in RPMI containing 1 mM Na pyruvate and
10 mM HEPES. All media were supplemented with either
10 % foetal bovine serum or 10 % charcoal-stripped foetal
bovine serum (both from PAA) and maintained at 37 °C
without antibiotics in a humidified atmosphere containing
95 % air and 5 % CO2.
RT-PCR
LNCaP or VCaP cells were grown in medium containing
charcoal-stripped serum to approximately 70 % confluence
and then cultured for a further 24 h in complete medium
containing either 10 nM DHT or ethanol vehicle. Extraction
of RNA and RT-PCR were carried out as described earlier
[32]. Semiquantitative PCR for hAR and GAPDH was per-
formed under conditions of linear amplification (30 and 26 cy-
cles of amplification for hAR and hGAPDH, respectively)
using the primers: hAR-Forward, 5′-TATCCCAGTCCCAC
TTGTGTC-3′; hAR-Reverse, 5′-CTTGTGCATGCGGTAC
TCATTG-3′; GAPDH-Forward, 5′-CGGAGTCAACGGAT
TTGGTCG-3′ and GAPDH-Reverse, 5′-CAATGCCAGCCC
CAGCGTCA-3′. The GAPDH primers were specific for
mRNA and did not amplify pseudogenes. The resulting
DNA products were resolved by 2.0 % agarose gel electro-
phoresis in TAE buffer (40 mM Tris-acetate, 1 mM EDTA
pH 8.3) and visualised by ethidium staining. Integration anal-
ysis of gels made use of the Image J software package using
exposures that contained no pixel saturation.
Plasmids and Site-Directed Mutagenesis
The luciferase reporter plasmid phAR1.6Luc, in which lucif-
erase expression is driven by the promoter and 5′ UTR of the
human androgen receptor gene, was created using the
promoterless firefly luciferase vector pGL4.17 (Promega).
The region of the human AR gene spanning between −741
and +842 was amplified by PCR using human male placental
genomic DNA template (Cambio), the oligonucleotides 5′-
GTTTACAGAGCTCTGGACAAAATT-3′ and 5′-TTCAAA
AGATGCCCAGATCTTAAAA-3′, and Pfu Turbo ultrahigh
fidelity DNA polymerase from Stratagene. The cloned hAR
genomic DNA was digested with SacI and BglII (sites
underlined in the PCR primers) and ligated into the SacI and
BglII sites in the vector.
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Both half sites within a potential androgen response ele-
ment (ARE) in the hAR 5′UTR of phAR1.6Luc were mutated
using the QuikChange II Mutagenesis kit (Agilent
Technologies) according to the manufacturer’s protocol.
Mutagenesis was performed in two sequential rounds to create
phAR1.6Luc-AREm using the following oligonucleotides
with their reverse complements (mutated bases shown in bold
font): AREm1, 5 ′-GGTTAGGCTGCACGCGGAGA
CTGTCCTCTGTTTTCCCCCAC-3′ followed by AREm2
5′-CACGCGGAGACTGTCCTCGCAGTTCCCCCACTCT
CTCTCC-3′. The integrity of all constructs was confirmed by
DNA sequencing.
Transfection and Luciferase Reporter Gene Assays
Twenty-four-well plates were seeded with LNCaP and VCaP
cells at a density of 5×104 cells/cm2, while DU145 cells were
seeded at a density of 1.2×104 cells/cm2. The cells were
cultured in complete medium for 24 h, then transfected with
440 ng/well of either firefly luciferase reporter plasmid alone
or cotransfected with pSVARo human androgen receptor ex-
pression plasmid (2:1 ratio) using jetPEI polyethylenimine
transfection reagent (Polyplus Transfection) according to the
manufacturer’s protocol. After 24 h, the mediumwas replaced
and the cells were cultured for a further 48 h.
Plasmid transfection was performed in quadruplicate and
luciferase activity was measured in duplicate by using a
GloMax 96 Microplate luminometer (Promega) and normal-
ised for protein concentration as previously described [33].
Preparation of Nuclear Extracts and Purified Human
Androgen Receptor
Nuclear extracts were prepared from LNCaP cells in the
presence of protease inhibitors (complete protease inhibitor
cocktail from Roche plus 1.0 mM PMSF) and protein phos-
phatase inhibitors (5 mM β-glycerophosphate and 100-μM
activated Na3VO4) using the method of Dignam et al. [34].
GST-tagged proteins encompassing the hAR N-terminal
domain (NTD) plus DNA-binding domain (DBD) or DBD
alone (amino acids 1–645 and 529–645, respectively, with
numbering based on hAR with NTD repeats of 21 glutamines
and 16 glycines) were expressed and purified as described
previously; the GST tags were removed by digestion with
thrombin (GE Health Care) [35]. The protein concentration
of nuclear extracts and hAR fragments were determined using
the Bio-Rad DC Protein Assay (Bio-Rad) with BSA as a
standard.
Electrophoretic Mobility Shift Assays
Either 10 μg LNCaP cell nuclear extract or 200 nM recombi-
nant hAR-DBD or hAR-NTD-DBD proteins were incubated
with 20 fmol biotin 3′ end-labelled double-stranded DNA
oligonucleotides using previously described conditions. The
forward sequences of the oligonucleotides were as follows:
ARE, 5′-ACGCGGAGAGAACCCTCTGTTTTCCCCCAC-
3′; AREm, 5′-ACGCGGAGACTGTCCTCGCAGTTCCC
CCAC-3′; and PSA-ARE-III, 5′-ACTCTGGAGGAACATA
TTGTATCGATTGTC-3′. Unlabelled versions of these oligo-
nucleotides, along with a random oligonucleotide (RO), 5′-
CGAGCACCCTTCACCCTCCAGGCTTAACGG-3′, con-
taining no regulatory elements were used for competition
assays in which they were added 15 min prior to the labelled
probe. Similarly, AR441 antibody against human androgen
receptor (sc-7305, SantaCruz Biotechnology) was added
15 min prior to the addition of labelled probe for supershift
assays.
The resulting DNA:protein products were resolved in
cooled 6 % nondenaturing polyacrylamide gels run in 0.5×
TBE buffer, pH 8.3 (45 mM Tris-borate, 1 mM EDTA) and
detected using Pierce LightShift Chemiluminescent reagents
(Thermo Scientific) according to the manufacturer’s protocol.
Figures were compiled using autorads of electrophoretic mo-
bility shift assay (EMSA) gels with the order of lanes within
some gels being altered to aid clarity and facilitate compari-
sons. Digital integration of the DNA:protein complexes was
carried out using a Vilber Loumat Fusion SL cooled CCD
sensor with care being taken to ensure that no pixel saturation
occurred.
Chromatin Immunoprecipitation Assay
A detailed account of the chromatin immunoprecipitation
(ChIP) methodology is presented in Elec t ronic
Supplementary Material. In brief, LNCaP cells were
transfected with either phAR1.6Luc or phAR1.6Luc-AREm
and later treated with either 10 nM DHT or vehicle for 4 h.
Cells were fixed in 1 % formaldehyde for 10min at 37 °C, and
nuclei were prepared. Chromatin and plasmid were digested
with 400 units each PvuII (NEB) and NheI (Roche) for 15min
at 37 °C; followed by lysis and the removal of insoluble debris
by centrifugation. The supernatant was diluted in ChIP buffer
and precleared using Protein G and Protein A Dynabeads
(Life Technologies). Samples of cleared lysates were retained
as input (IP), and the remainder was incubated with either anti-
hAR antibody (PG21, 06-680 Millipore) or IgG.
Immunocomplexes were collected by magnetisation, washed
twice each with low salt, high salt and LiCl and TE buffers,
followed by elution. DNA-protein cross-links were reversed
with NaCl and DNA purified. Isolated DNAwas quantified by
semiquantitative log phase PCR and resolved by agarose gel
electrophoresis in TAE buffer. The forward (F) and reverse (R)
primers were as follows: ARE-F, 5′-CATTGCAAAGAAGG
CTCTTAGG-3′; Cont-F, 5′-CCCGAGTTTGCAGAGAGG
TA-3′; Gen-R, 5′-GGACAAGATCTGCCCTGCTA-3′; Vect-





The statistical significance of differences in data sets of
DNA:protein complex formation in EMSA experiments was
determined using two-way ANOVA, and paired t-test analysis
of variance was employed for all other comparisons between
complementary data.
Results
A Primate-Specific Androgen Response Element Is Present
in Human AR Gene 5′ UTR
Autoregulation of the AR gene by androgens is likely to play
an important role during development and in conditions where
circulating androgen levels have been reduced. To confirm
earlier observations that androgens downregulate AR gene
expression, LNCaP and VCaP cells were treated with 10 nM
DHT followed by isolation of the RNA. Figure 1a shows that,
relative to the transcript of the housekeeping enzyme
Fig. 1 Non-consensus ARE in
hAR 5′ UTR. a Semiquantitative
RT-PCR analysis of endogenous
AR gene expression in LNCaP or
VCaP cells following treatment
with either 10 nMDHTor ethanol
vehicle. The data represent the
means±SD of at least three
independent experiments and
statistical significances are the
following: **p<0.01;
***p<0.001. b Diagrammatic
representation of the human AR
gene proximal promoter and 5′
UTR showing the principal
regulatory elements and putative
nonconsensus ARE. Bent arrow
indicates the transcriptional start
site (+1) and ATG with solid
arrow shows the start of
translation. c Alignments of the
putative ARE region in AR gene
5′ UTRs of the indicated species
with the two half sites demarked
by boxes. Differences from the
human sequence are indicated by
bold, underlined font
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GAPDH, transcription of the hAR gene in the absence of
androgen was markedly higher in VCaP than in LNCaP
(p<0.01). Conversely, treatment with androgen reduced AR
mRNA in VCaP to a much greater degree than in LNCaPwith
values of 80 and 48 %, respectively.
Bioinformatic analysis of publically available DNA se-
quences was used to identify possible AREs in the promoter
and adjacent proximal and distal sequences of the human
androgen receptor (hAR) gene. Only a previously described
suggested nonconsensus ARE (AGAACCctcTGTTTT) at po-
sition 611 bp in the 5′ UTR of exon 1 [36] was revealed
(Fig. 1b). The putative ARE contains two half sites which
are separated by three nucleotides and form a partial palin-
dromic repeat; analogous to a canonical class 1 ARE.
Comparison of the equivalent region of the AR gene 5′ UTR
in 13 species using multiple alignments (Fig. 1c) showed that
this sequence is present only in primates. Gorilla, which
diverged from humans 8.6 million years ago [37], has a
perfect homology with human, and over the span of
42.2 million years from the divergence of humans and mar-
moset, the most distant primate examined, the majority of
sequences show only a single nucleotide substitution. This is
in marked contrast to all of the nonprimate species which
possess low levels of homology with human, and no equiva-
lent sequence was found in fish species.
Androgen Receptor Binds to the Putative ARE
The possibility that hAR binds to the nonconsensus ARE was
examined by electrophoretic mobility shift assays (EMSAs).
In initial experiments, purified hAR protein encoding the N-
terminal domain (NTD) and DNA-binding domain (DBD),
i.e. amino acids 1 to 645 was incubated with labelled oligo-
nucleotide probe (ARE) containing the putative 5′ UTR ARE.
Electrophoretic resolution of the resulting products showed a
single high molecular weight DNA:protein complex near the
top of the gel (Fig. 2a, lane 1). In addition, Fig. 2a lanes 1 and
8 show that this DNA:protein complex had very similar
characteristics to that created with a labelled oligonucleotide
(PSA-ARE-III) encoding the well-characterised, active ARE
present in the upstream enhancer of the androgen-regulated
PSA gene at position −4,200 bp [38]. Binding of hAR NTD-
DBD to oligonucleotide ARE was unaffected by
preincubation with an excess of a random oligonucleotide
(RO) containing no regulatory elements as determined by
TRANSFAC analysis or one in which both half sites of the
ARE had been mutated (AREm); however, oligonucleotides
ARE and PSA-ARE-III completely prevented DNA:protein
complex formation (Fig. 2a, lanes 2 to 5, respectively).
Preincubation with preimmune serum had no effect on bind-
ing of hARNTD-DBD to either oligonucleotide ARE or PSA-
ARE-III (Fig. 2a, lanes 6 and 9, respectively), whereas anti-
hAR antibody AR441, against an epitope between amino
acids 299 and 315 in the NTD, effectively blocked binding
of hAR to both oligonucleotides (Fig. 2a, lanes 7 and 10,
respectively). Incubation of hAR NTD-DBD with labelled
oligonucleotide containing the mutated form of the ARE
failed to produce DNA:protein complex (Fig. 2a, lanes 11
and 12). Similar results were observed using just the DNA-
binding domain of hAR (amino acids 529 to 645) and are
shown in Supplemental Fig. 1a.
Incubation of nuclear extract prepared from the AR ex-
pressing prostate cancer cell line LNCaP with either ARE or
PSA-RE-III oligonucleotides produced several bands with
virtually identical electrophoretic motilities, but not with the
mutated AREm (Fig. 2b, lanes 1, 8 and 7, respectively).
Binding of hAR to ARE was confirmed by addition of anti-
hAR antibody AR441 which completely prevented assembly
of a high molecular weight DNA:protein complex with both
ARE and PSA-ARE-III (Fig. 2b, lanes 3 and 10, respectively),
Fig. 2 Androgen receptor binds to the 5′ UTR ARE. Purified hAR
protein or nuclear extract from LNCaP cells were incubated with the
labelled oligonucleotide probes indicated below each gel and the products
resolved by electrophoretic mobility shift analysis. Competing unlabelled
oligonucleotides (100-fold molar excess) or immune sera added prior to
addition of probe are shown above the gels. EMSAs are representative of
at least three independent experiments. a Purified hAR protein encoding
the NTD and DBD (residues 1–645) was incubated with labelled probe.
Additions were the following: RO a random oligonucleotide; PI
preimmune serum and Ab, anti-hAR-NTD antibody. b Nuclear extract
from AR-expressing LNCaP cells was incubated with labelled probe, and
the complex absent after incubation with antibody is indicated by the
marker. These gels were electrophoresed for an additional 30 min to
resolve the high molecular weight complexes
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while preimmune serum (PI) had no effect (Fig. 2b, lanes 2
and 9). Competing oligonucleotides lacking ARE sites, i.e.
RO and AREm, failed to inhibit DNA:protein complex for-
mation with both ARE and PSA-ARE-III probes (Fig. 2b,
lanes 4 and 5 and 11 and 12, respectively) while positive
controls using 50- or 100-fold excess of unlabelled self-
competitors did (Fig. 2b, lanes 6 and 13).
Comparative Affinities of 5′ UTR ARE and PSA-ARE-III
for hAR
The EMSA in Fig. 2a suggested differential binding of hAR
NTD-DBD to the 5′ UTR ARE in comparison to PSA-ARE-
III. This was investigated further by carrying out a series of
EMSAs using a constant amount of these labelled probes after
preincubation of a fixed amount of hAR protein with a range
of excess competing unlabelled oligonucleotide, followed by
integration of the digital gel images (Fig. 3). The results
showed that competing PSA-ARE-III oligonucleotide
prevented hAR NTD-DBD binding to ARE much more ef-
fectively than the converse situation (Fig. 3, p<0.001). A
similar finding was obtained using the hAR DBD
(Supplemental Fig. 1b, p<0.001). Together these results show
that hAR binds to the nonconsensus 5′UTR ARE; however, it
does so with lower affinity than to ARE-III in the PSA
enhancer.
The 5′ UTR ARE Downregulates Promoter Activity
In order to determine whether the putative ARE had in vivo
functional activity, a 1.6-kbp section of the hAR promoter and
5′ UTR (between positions −741 to +842 bp) was cloned into
the pGL4.17 promoterless luciferase reporter plasmid to create
phAR1.6Luc (Fig. 4a). This region contains the crucial GC
box in the TATA-less promoter and the main regulatory ele-
ments (see Fig. 1a), thus ensuring that the putative AREwould
operate in a normal, physiologically relevant manner. Initial
experiments involved studying the response of phAR1.6Luc
to androgen in several prostate cancer cell lines by carrying
out transient transfection followed by treatment with either
10 nM DHT or vehicle. The results in Fig. 4b (left panel)
show that DHT downregulated transcriptional activity of
the promoter by 59 and 45 % in LNCaP and VCaP, respec-
tively (p<0.001 in both instances). The lower reduction
seen in VCaP compared to LNCaP may reflect the pres-
ence of multiple androgen insensitive and constitutively
active splice variants in the former cell line [39]. In con-
trast, DU145 cells, which lack AR, completely failed to
respond to DHT (p>0.85); however, cotransfection with
the hAR expression plasmid pSVARo led to 48 % DHT-
induced downregulation (p<0.001). Treatment of DU145
cells expressing the hAR with the antiandrogens,
bicalutamide (Bic) or enzalutamide (Enz) failed to repress
luciferase activity (Fig. 4b, right panel). In addition,
Fig. 3 The nonconsensus 5′UTR
ARE has lower affinity for hAR
than does a consensus ARE. a
Comparison of the 5′ UTR ARE
and PSA-ARE-III
oligonucleotides used in EMSAs.
b Human AR NTD-DBD was
incubated with either labelled
ARE probe and competed by
preincubation with PSA-ARE-III
oligonucleotide (dashed line) or
labelled PSA-ARE-III probe and
competed with ARE
oligonucleotide (solid line). The
molar excess of unlabelled
competing oligonucleotide is
shown above representative
EMSAs. Data presented in the
graphs were generated using
unsaturated images, and the
values are the means of a
minimum of three independent
experiments±SD
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inclusion of antiandrogen with DHT antagonised the
androgen-induced repression (data not shown). Therefore,
the phAR1.6Luc plasmid behaved in a physiological man-
ner and displayed agonist induced auto-downregulation
that was mediated through the AR.
The next step was to mutate the putative ARE to create the
reporter construct phAR1.6Luc-AREm (Fig. 4a) and deter-
mine the effect on transcriptional activity. In order to confirm
TRANSFAC analysis that no new regulatory elements had
been created by mutation, initial experiments were performed
Fig. 4 The 5′UTR ARE downregulates promoter transcriptional activity.
a Schematic representation of the 1.6-kbp section of the hAR promoter
and 5′ UTR used to drive luciferase expression in reporter construct
phAR1.6Luc. Bent arrow indicates the transcriptional start site and mu-
tation of the ARE half sites (boxed) are underlined. b Effect of DHT and
antiandrogens on hAR promoter activity in PCa cell lines. Left panel: the
indicated PCa cell lines were transfected with phAR1.6Luc containing
the WT ARE and treated with either 10 nM DHT or vehicle. The values
show luciferase activity in cells treated with DHT relative to those
cultured in vehicle for each given cell line. Right panel: luciferase activity
for DU145 cells expressing the hAR treated with 10 μM bicalutamide
(Bic) or 10 μM enzalutamide (Enz) relative to those cultured in vehicle.
Mean±SD for a representative experiment. c The indicated PCa cell lines
were transfected with either phAR1.6Luc (WT) or phAR1.6Luc-AREm
(AREm) and cultured in complete medium. The values show luciferase
activity of the mutated reporter plasmid relative to that encoding the WT
ARE for each cell line. d The PCa cell lines LNCaP and VCaP were
transfected with either phAR1.6Luc (WT) or phAR1.6Luc-AREm
(AREm) and treated with 10 nM DHT or vehicle. The values show
luciferase activity in cells treated with DHT relative to those cultured in
vehicle for each given cell line and plasmid. Luciferase data represent the
means±SEM of at least three independent experiments and the statistical
significance of the indicated comparisons are the following: *p<0.05;
**p<0.01; ***p<0.001
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using PCa cells cultured in complete medium containing
foetal bovine serum rather than charcoal stripped serumwhich
is depleted in some components e.g. growth factors and hor-
mones, to ensure that all cell signalling pathways were fully
operational. Direct comparison of the WT hAR promoter and
that containing the mutated 5′UTRARE in Fig 4c reveals that
loss of the 5′ UTR ARE led to increases of 48 and 46 % in
promoter activity in LNCaP and VCaP cells, respectively
(both p<0.001). While LNCaP cells express AR but not
glucocorticoid receptor (GR), the converse occurs in DU145
cells [40], and in these cells, mutation of the 5′UTR ARE had
no effect (p>0.34), thus confirming that no new regulatory
element had been created, and that GR does not interact with
this ARE. However, cotransfection of DU145 cells with the
pSVARo hAR expression plasmid resulted in the 5′UTRARE
mutation raising transcriptional activity by 25 % (Fig. 4c,
p<0.001). Together, these results show that AR binds to the
5′ UTR ARE to downregulate transcription and mutation of
the site leads to a release of this repression.
Lastly, the role of the 5′ UTR ARE in contributing to
androgen auto-downregulation of the hAR promoter was con-
firmed by looking at the effect of the site’s mutation on DHT-
induced repression in LNCaP and VCaP cells. The results
presented in Fig. 4d, in which DHT-induced repression is
expressed as luciferase activity in 10 nM DHT relative to that
in the absence of androgen, show that mutation of the 5′ UTR
ARE diminished DHT repression from 59 to 43 % in LNCaP
and from 45 to 24 % in VCaP (both p<0.01). Interestingly,
from Fig. 4d it can be seen that the luciferase reporter plasmids
containing the mutated 5′ UTR ARE continue to be subject to
androgen downregulation in both LNCaP and VCaP (p<0.01
in both instances), albeit to a much lesser degree.
hAR Binds to the Endogenous 5′ UTR ARE
Because the conditions of EMSA incubations cannot always
reflect the chromatin environment, ChIP assays were under-
taken to look at AR binding to the endogenous hAR 5′ UTR
ARE site. In order to study the regulatory element in its native
state and to compare the effects of its mutation, LNCaP cells
were used directly or transiently transfected with either
phAR1.6Luc or phAR1.6Luc-AREm containing the WT or
mutated ARE, respectively, and treated with either vehicle or
10 nM DHT. Initial experiments to confirm the specificity of
the PG21 anti-hAR antibody were performed using the well-
characterised promoter and enhancer regions of the psa gene
which contains three active AREs, and the results are shown
in Supplemental Fig. 2. PCR amplification of the AREs
demonstrated binding of the PG21 antibody; however, ampli-
fication of a region in the middle of the promoter distant from
the AREs failed to produce a signal.
Chromatin and plasmid were digested with NheI and PvuII
in order to isolate the region of the 5′ UTR under study in the
ChIP experiments from a previously described potential AR
binding site proximal to the 5′UTRARE [30], and solubilised
DNA was precipitated using anti-hAR antibody. Figure 5a
depicts the hAR 5′ UTR along with the cleavage sites for
NheI and PvuII, and the relative positions of the oligonucle-
otides used for semiquantitative PCR amplification. A for-
ward primer upstream of the 5′ UTR ARE (ARE-F) was
utilised in conjunction with either of two different reverse
primers which were specific for the genomic sequence (Gen-
R) or the plasmid vector (Vect-R). The effectiveness of endo-
nuclease cleavage of both genomic chromatin and plasmid
DNA was confirmed by PCR amplification of ChIP DNA
input samples using the control forward oligonucleotide
(Cont-F), which lies upstream of an NheI site (Fig. 5a), and
the appropriate reverse primer (Supplemental Fig. 3).
An t i - hAR an t i body, bu t no t p r e immune Ig ,
immunoprecipitated the 5′ UTR ARE region of the AR gene
in LNCaP cells that had been treated with either vehicle or
DHT (Fig. 5b). This result is in agreement with the fact that
LNCaP cells express the T877A mutated form of AR which
has a high constitutive transcriptional activity even in the
absence of androgen [33]. Integration of unsaturated digital
gel images and calculation of immunoprecipitated DNA rela-
tive to input DNA showed that treatment with 10 nMDHT led
to a 2.5-fold increase in AR binding to the genomic 5′ UTR
ARE (p<0.05). PCR amplification of precipitated DNAwith
oligonucleotide primers encompassing the active ARE-III site
in the human PSA upstream enhancer (Fig. 5b) confirmed the
efficacy of the ChIP methodology. Similarly, anti-hAR
antibody-precipitated phAR1.6Luc plasmid DNA in
transfected LNCaP cells was PCR-amplified using the same
5′ UTR forward primer (ARE-F) and the vector-specific re-
verse primer (Vect-R). From Fig. 5c, it can be seen that, as
with the genomic regulatory element, hAR binds to the 5′
UTR ARE in vivo both in the absence and presence of DHT.
Similarly, integration of PCR gels showed that binding of AR
to the ARE is increased 2.7-fold (p<0.01) in the presence of
androgen. On the other hand, hAR failed to bind to the 5′UTR
ARE of the luciferase reporter plasmid in which both half sites
of the ARE had been mutated (phAR1.6Luc-AREm), regard-
less of the presence of hormone (p>0.51 and p>0.75 for
vehicle and DHT, respectively).
Discussion
Enduring expression of the androgen receptor in PCa contrib-
utes to tumour survival and proliferation as well as facilitating
progression to fatal CRPC status. Therefore, it is vital to
understand the molecular mechanics of human AR gene reg-
ulation; especially the negative feedback loop whereby
ligand-activated AR downregulates transcription of its own
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gene, since androgen deprivation therapy (ADT) is the prin-
cipal strategy of advanced PCa treatment regimes. In this
study, we have identified an ARE in the 5′ UTR of the human
AR gene and confirmed binding of AR to it by EMSA using
both purified AR and LNCaP nuclear extract and ChIP assays.
Importantly, luciferase measurements of transcriptional activ-
ity in PCa cell lines established that the 5′ UTR ARE
downregulates expression in response to androgens, and dis-
ruption of this ARE alleviates repression in an AR-dependent
manner. Furthermore, the clinically relevant antiandrogens,
bicalutamide and enzalutamide were unable to mediate
receptor-dependent repression. These observations were made
independently of Vismara et al. [36] who suggested a putative
nonclassical ARE in the 5′ UTR. In contrast to that study, we
Fig. 5 ChIP analysis confirms binding of hAR to 5′ UTR ARE. a Line
diagram (not to scale) of the hAR 5′UTR showing the recognition sites of
the restriction endonucleases NheI and PvuII used to digest chromatin
and plasmid, plus the forward (F) and reverse (R) primers (solid arrows)
used for ChIP semiquantitative PCR. Oligonucleotides Gen-R andVect-R
are specific for the genomic and plasmid vector sequences, respectively,
and the bent arrow indicates the transcriptional start site. b, c and d
Representative agarose gels of PCR amplified immunoprecipitated
DNA. b LNCaP cells were treated with either vehicle or 10 nM DHT
(shown above gel) and ChIP was performed using PG21 anti-hAR
antibody. Precipitated genomic DNA was amplified using primers for
the ARE in the hAR 5′ UTR (ARE), or in the PSA upstream promoter
(PSA-ARE-III) with DHT treated cells. Lanes: IP input sample, Ig
preimmune rabbit IgG, Ab antibody. Charts display values expressed as
percentage of input DNA and represent means±S.D, *p<0.05;
**p<0.01. c LNCaP cells were transfected with either phAR1.6Luc or
phAR1.6Luc-AREm and subsequently treated with either vehicle or
10 nM DHT (both shown above gels). ChIP was carried out using
PG21 anti-hAR antibody and the 5′ UTR ARE in precipitated plasmid
amplified by PCR. Lanes and charts are as in panel b
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have demonstrated the binding of AR and functional rele-
vance of this element in different prostate cell lines.
The adverse nature of the AR’s influence on PCa progres-
sion is manifested from the several lines of evidence.
Androgen activation of AR limits proliferation of prostate
epithelial cells in keeping with its role of promoting terminal
differentiation [41, 42]. However, the AR usually increases
proliferation of PCa cell lines [43, 44] and receptor inhibition
results in repression of CRPC tumour growth [23]. Reduction
of AR synthesis in both androgen sensitive (AS) and CRPC
cells by RNA interference has revealed a correlation between
AR expression and cell viability [45]. However, the escape of
CRPC from hormone regulation is not due simply to increased
amounts of AR, as the receptor directs expression of a distinct
transcriptome that contributes to the ability to grow in an
apparently androgen independent manner [46–48].
In order to maintain AR levels within narrow constraints in
normal cells, the AR gene is under the control of multiple
regulatory elements. In terms of hAR gene autoregulation,
activated AR can stimulate expression through an exonic
enhancer about 170 kbp distal from the promoter where
specificity for AR is dependent upon the structure of the
receptor ’s NTD [31] . Androgen receptor au to-
downregulation can occur through a repressor ARE in the
second intron of the hAR gene 130 kbp downstream of the
promoter [30] and the 5′ UTR ARE described in this report.
Although sequence analysis reveals no other potential AREs
in the promoter and 5′ UTR between −741 to +842 bp, the
binding of AR to a site between −225 and +504 bp has been
reported [30]. It must be emphasised that the repressor 5′UTR
ARE described in this report is distinct from that AR binding
site as confirmed in the ChIP assays which differentiated
between the two AR binding sites by restriction endonuclease
digestion between them (Supplemental Fig. 3). The 5′ UTR
ARE described here is also distinct from the AR binding site
identified upstream of the gene promoter [49]. This site (chro-
mosomal location 66,237–66,248 kbp) was associated with a
binding site for the ETS transcription factor, ERG, and ERG-
dependent repression of the AR gene.
Interestingly, while mutation of the 5′ UTR ARE in the
reporter plasmid, which did not contain the intronic repressor
ARE, significantly lessened AR-dependant downregulation in
the PCa cell lines examined, this repression was not complete-
ly abolished (Fig. 4d). Our data are consistent with earlier
observations that deletion of the section from +570 to +
1,025 bp (containing the 5′ UTR ARE) in luciferase reporters
driven by the hAR promoter and 5′ UTR does not completely
abrogate downregulation by androgens [36]. A growing body
of work has elucidated some of the signalling pathways by
which this can occur through the regulatory elements present
in the luciferase reporter (Fig. 1b). The dominant transcription
factor driving AR expression is Sp1 that binds to several sites
in the core promoter and 5′ UTR. DHT-activated AR can
inhibit Sp1 transactivation without binding to chromatin by
directly interacting with the transcription factor and interfering
with its binding to its regulatory elements. Within PCa cells,
this process has been found to downregulate Sp1-directed
expression of c-Met in WR22Rv1 cells and LNCaP xeno-
grafts [50] and Smad3 in the PCa cell lines NRP-154AR,
DU145AR, LNCaP and VCaP [51]. Another route operates
through the transcription factor TWIST1 which upregulates
hAR expression [52]. Expression of TWIST1 is repressed by
androgens in PCa cells through a process mediated by NKX3-
1. In brief, androgens strongly upregulate NKX3-1 production
in prostate epithelial cells [53, 54] and in PCa cells where
upon NKX3-1 binds to the TWIST1 promoter to strongly
repress transcription [55]. An active cyclic AMP-responsive
element (CRE) in the hAR promoter [56] increases AR tran-
scription in response to cAMP signalling. Members of the
CREB/ATF family bind to CRE sites and in turn bind CREB
binding protein (CBP) which forms a bridge with the basal
transcription apparatus. Androgen-activated AR in PCa cells
can sequester CBP without binding to DNA, thereby
squelching transcription involving CBP [57]. Another mem-
ber of the CREB/ATF family that binds CRE sites, ATF3, is a
repressor [58] and is overexpressed in many cancer cells. In
LNCaP, its expression is strongly upregulated by DHT [54]
which would lead to downregulation of promoters with CRE
sites. Lastly, two of the eight NF-κB binding sites in the hAR
promoter proximal to the initiation site that increase AR
transcription upon binding of p 50 and RelA (p65) in PCa
cells [59] are present in the reporter plasmid. Androgen acti-
vation of AR reduces expression, nuclear localisation and
transcriptional activity of RelA in PCa cells [60]. Together,
auto-repression of the hAR gene through multiple avenues
provides redundancy to protect against the consequences of
mutation and a means of fine tuning expression of a powerful
developmental gene.
One of the routes by which AR regulates target gene
expression is through epigenetic remodelling of chromatin.
An example is the recruitment of lysine-specific demethylase
1 (LSD1) by activated AR to its associated ARE where it can
behave as a corepressor or coactivator [61]. Indeed, the afore-
mentioned ARE repressor regulatory element in the second
intron has recently been shown to downregulate AR expres-
sion through AR binding and the action of LSD1 [30].
However, we found no evidence that LSD1 is recruited to
the ARE in the 5′ UTR (Supplemental Fig. 4); therefore,
another of the many mechanisms of ARE-based repression
is most likely involved [62].
Another significant finding was that the 5′ UTR ARE is
confined to primates with the equivalent region in other spe-
cies, especially the rodents, rat and mouse, displaying partic-
ularly low homology. This strongly suggests that caution
should be exercised when using rodent models to investigate
regulation of the AR gene.
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In conclusion, pertinacious AR signalling is implicated in
the progression to CRPC with the levels of the receptor
mediating the life and death of tumours. The repressor ARE
we have characterised in the 5′ UTR lends valuable insight
into the control of AR expression and will provide targets for
novel therapeutic agents against CRPC. The finding that AR
expression is downregulated by androgens through multiple
sites raises the question of whether ADT can on occasion be
counterproductive as a consequence of transcriptional repres-
sion being alleviated. In addition, DHT can have an indirect
protective role as it has recently been found to inhibit the
induction of autoimmune and inflammatory responses in hu-
man prostatic stromal cells [63]. Thus, the benefits of ADT
must be balanced with a consideration of the risks and perhaps
more attention should be focused on bipolar androgen therapy
(BAT) [64, 65] in which acute ablation and supraphysiologic
levels of androgen are alternated in rapid cycles to prevent
PCa cells adapting their AR expression in response to envi-
ronmental conditions.
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